Search

Author/Creator Magoon, Daniel

1. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Issue 10 (13th May 2015)

Authors:
Loh, Mignon L.; Tasian, Sarah K.; Rabin, Karen R.; Brown, Patrick; Magoon, Daniel; Reid, Joel M.; Chen, Xuejun; Ahern, Charlotte H.; Weigel, Brenda J.; Blaney, Susan M.
Journal:
Pediatric blood & cancer
Issue:
Volume 62:Issue 10(2015:Oct.)
Page Start:
1717
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10‐03). Issue 8 (14th April 2017)

Authors:
Cooper, Todd M.; Sison, Edward Allan Racela; Baker, Sharyn D.; Li, Lie; Ahmed, Amina; Trippett, Tanya; Gore, Lia; Macy, Margaret E.; Narendran, Aru; August, Keith; Absalon, Michael J.; Boklan, Jessica; Pollard, Jessica; Magoon, Daniel; Brown, Patrick A.
Journal:
Pediatric blood & cancer
Issue:
Volume 64:Issue 8(2017)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗